Following a positive opinion from the European Medicines Agency (EMEA ) in February 2008, the Commission last week granted market authorisation for Prepandrix™ – the first pre-pandemic vaccine for humans against influenza caused by the H5N1 virus.
Following a positive opinion from the European Medicines Agency (EMEA ) in February 2008, the Commission last week granted market authorisation for Prepandrix™ – the first pre-pandemic vaccine for humans against influenza caused by the H5N1 virus.